Author:
Mangoni Arduino A.,Zinellu Angelo,Sotgia Salvatore,Rowland Andrew,Carru Ciriaco
Reference100 articles.
1. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 2010;77:44–50.
2. Albsmeier J, Schwedhelm E, Schulze F, et al. Determination of NG, NG-dimethyl-l-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;809:59–65.
3. Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG, NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437–42.
4. Arikan E, Karadag CH, Guldiken S. Asymmetric dimethylarginine levels in thyroid diseases. J Endocrinol Invest. 2007;30:186–91.
5. Aucella F, Maas R, Vigilante M, et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis. 2009;207:541–5.